Grégoire CourtineGrégoire Courtine was originally trained in Mathematics and Physics, but received his PhD degree in Experimental Medicine from the University of Pavia, Italy, and the INSERM Plasticity and Motricity, in France, in 2003. From 2004-2007, he held a Post-doctoral Fellow position at the Brain Research Institute, University of California at Los Angeles (UCLA) under the supervision of Dr. Reggie Edgerton, and was a research associate for the Christopher and Dana Reeve Foundation (CDRF). In 2008, he became Assistant Professor at the faculty of Medicine of the University of Zurich where he established his own research laboratory. In 2012, he was nominated Associate Professor at the Swiss Federal Institute of Technology Lausanne (EPFL) where he holds the International paraplegic foundation (IRP) chair in spinal cord repair at the Center for Neuroprosthetics and the Brain Mind Institute. He published several articles proposing radically new approaches for restoring function after spinal cord injury, which were discussed in national and international press extensively. He received numerous honors and awards such as the 2007 UCLA Chancellors award for excellence in post-doctoral research and the 2009 Schellenberg Prize for his innovative research in spinal cord injury awarded by the International Foundation of Research in Paraplegia.
Giorgio MargaritondoCitizen of the USA and Switzerland, Giorgio Margaritondo was born in Rome, Italy, in 1946. He received the Laurea summa cum laude from the University of Rome in 1969. From 1969 he was an employee of the Italian National Research Council in Rome and Frascati and, in 1975-77, he was at Bell Laboratories in the USA. From 1978 to 1990, he was professor of physics at the University of Wisconsin-Madison in the USA; in 1984 he was nominated associate director for research of the Synchrotron Radiation Center of the same university. In 1990 he was nominated "professeur ordinaire" (full professor) at the EPFL; he directed the Institute of Applied Physics and the Physics Department. He was also a honorary faculty member at Vanderbilt University in Nashville. In 2001 he became Dean of the EPFL Faculty of Basic Sciences. In 2004 he was nominated Provost and he served until 2010, when he became Dean of Continuing Education, until his retirement from the EPFL in 2016 In addition to teaching general physics, his activity concerns the physics of semiconductors and superconductors (electronic states, surfaces and interfaces) and of biological systems; his main experimental techniques are electron spectroscopy and spectromicroscopy, x-ray imaging and scanning near-field microscopy, including experiments with synchrotron light and with free electron lasers. Author of more than 700 scientific publications and 9 books, he was also coordinator in 1995-98 of the scientific division of the Elettra synchrotron in Trieste. In 1997-2003 he was coordinator of the European Commission Round Table on synchrotron radiation, and then became president of the Council of the European Commission Integrated Initiative on Synchrotron and Free Electron Laser Science (IA-SFS and then ELISA), the largest network in the world in this domain. In 2011-15, he was Editor-in-Chief of Journal of Physics D (Applied Physics). He is currently vice-president of the council of the Università della Svizzera Italiana (USI), and president of the Scientific and Technological Committee of the Italian Institute of Technology (IIT). He is Fellow of the American Physical Society and of the American Vacuum Society and Fellow and Chartered Physicist of the Institute of Physics.
Lijing XinLijing Xin is a research staff scientist and 7T MR Operational Manager at the Center for Biomedical Imaging (CIBM), Ecole polytechnique fédérale de Lausanne (EPFL), Switzerland. Her research interests focus on developing cutting-edge magnetic resonance spectroscopy and imaging methods for better understanding the brain function and the pathophysiology of neurological diseases. Her journey on magnetic resonance imaging (MRI) started from her master project during 2002-2005, where she developed a gradient unit with eddy current compensation and a pulse sequence generator for MRI spectrometer, which enhanced her knowledge in MR instrumentation. Later, she obtained her PhD in physics from Ecole polytechnique fédérale de Lausanne (EPFL) in 2010, where she focused on developing various novel 1H and 13C magnetic resonance spectroscopy (MRS) acquisition and quantification methods as well as RF coils on high field preclinical MR scanners. Afterwards, she started working on the clinical MR platforms including both 3 and 7T and continued to improve and develop novel acquisition and quantification methods for 1H, 13C and 31P nuclei. She carries on interdisciplinary collaborations with different partners, particularly with clinical partners where translational strategies are performed to explore the pathophysiology of psychiatric disorders and disease biomarkers for early diagnose and intervention.
Hilal Lashuel2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies. 